Brief: Entera Bio Receives FDA Agreement On Bmd As Primary Endpoint For Eb613 Registrational, Phase 3 Study In Post-Menopausal Women With Osteoporosis
28/07/2025 12:40
July 28 (Reuters) - Entera Bio Ltd 5DT.F: ENTERA BIO RECEIVES FDA AGREEMENT ON BMD AS PRIMARY ENDPOINT FOR EB613 REGISTRATIONAL, PHASE 3 STUDY IN POST-MENOPAUSAL WOMEN WITH OSTEOPOROSIS Source text: ID:nGNX1t7Ysl Further company coverage: 5DT.F (Reporting by Anshi Sancheti) ((Anshi.Sancheti@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement